Identification of multi-drug resistant Acinetobacter baumannii phage YZ2 and evaluation of its therapeutic efficacy in vivo and in vitro
Abstract
Introduction: Carbapenem-resistant Acinetobacter baumannii (CRAB) has recently become an important pathogen in clinically acquired infections, making treatment more challenging.
Methods: The treatment of bacterial infections may improve with the development of phage therapy and phage-antibiotic combination therapy. Here, we reported a novel phage YZ2 that has a double-stranded DNA genome of 40,181 bp with 37.93% GC content. A total of 46 open reading frames (ORFs) and no virulence or antimicrobial resistance genes were annotated in the genome of phage YZ2. Phage YZ2 is a novel member of the Autographiviridae, with a latency period of approximately 20 min and a burst size of approximately 134 phage particles per infected host cell.
Results: The in vitro antibacterial results demonstrated that YZ2 could rapidly eliminate host bacteria at a low multiplicity of infection, showing strong bactericidal efficacy. In vivo, YZ2 significantly increased the survival rate of A. baumannii-infected Galleria mellonella larvae from 10 to 100% within 72 h.
Discussion: Moreover, compared with the use of phage or polymyxin B alone, the combined use of phage YZ2 and polymyxin B can significantly increased the survival rate of G. mellonella larvae and had a synergistic effect. These results imply that phage YZ2 has the potential for development as an antimicrobial agent.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.